Clinical Trial Detail

NCT ID NCT02698189
Title A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

acute myeloid leukemia

diffuse large B-cell lymphoma

Therapies

Birabresib

Age Groups: senior adult

No variant requirements are available.